GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Innoviva Inc.
Innoviva is a company that receives royalties from sales of respiratory drugs developed jointly with GSK. Its stock price reflects the stability of these cash flows. The chart is a history of passive income from successful blockbusters.
Share prices of companies in the market segment - Investors holding
Innoviva is a company that receives royalties from sales of respiratory drugs developed jointly with GSK. This is its core segment. We classify it as an Investor Holdings company, and the chart below reflects the dynamics of the entire intellectual property-based industry.
Broad Market Index - GURU.Markets
Innoviva is a holding company that owns royalties on respiratory drugs developed by GSK and invests in other companies. It is a component of the GURU.Markets index. The chart below represents the market. See how this unique business model compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
INVA - Daily change in the company's share price Innoviva Inc.
Daily fluctuations in Innoviva, the owner of royalties on respiratory drugs, reflect the stability of cash flows from these products. Change_co shows sensitivity to news from GSK, the main partner. This metric is key to analyzing the pharmaceutical royalty sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Investors holding
Innoviva, Inc. is a company that owns royalties on respiratory drugs. This chart shows the average daily volatility of the pharmaceutical sector. Comparing this to INVA, whose business is based on passive income, helps us appreciate its unique and stable business model.
Daily change in the price of a broad market stock, index - GURU.Markets
Innoviva is a holding company with royalty-bearing assets in respiratory pharmaceuticals. Its diversified model aims to mitigate risks in the volatile biotech sector. The chart below reflects average fluctuations in this industry, providing context for valuing Innoviva shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Innoviva Inc.
Innoviva is a holding company with interests in various industries. Its stock price performance represents the combined impact of these diverse businesses and contributes uniquely to the complex and multifaceted picture of overall market volatility.
Annual dynamics of market capitalization of the market segment - Investors holding
Innoviva, Inc. is a unique company that owns a portfolio of royalties on respiratory drugs from GSK. Its business is focused on generating passive income. The chart shows how its stable, highly profitable, but flat cash flow and diversification efforts influence its performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Innoviva, which owns royalties on popular drugs, has a unique business model. Its revenue is predictable and independent of the economy. The company's stock price is a story of how passive income from intellectual property generates a stable cash flow, making it more like a financial asset than a pharmaceutical one.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Innoviva Inc.
Innoviva, the owner of royalties on respiratory drugs, is valued at a stable rate. The monthly fluctuations on the chart reflect the predictable cash flows from the royalties it receives from GSK, making its business immune to short market cycles.
Monthly dynamics of market capitalization of the market segment - Investors holding
Innoviva, Inc. is a company with a unique business model, earning royalties from respiratory medications sold by GlaxoSmithKline. The dynamics of its sector, shown in the chart, serve as background. It's interesting to consider how a stable cash flow from royalties allows Innoviva to invest in new pharmaceutical assets, diversifying its business.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Investment holdings with pharmaceutical assets can exhibit mixed performance. The chart below illustrates the overall market sentiment. What influences Innoviva more: the defensive nature of pharmaceutical royalties or the volatility of its venture capital investments, which forces it to follow the market?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Innoviva Inc.
Innoviva, Inc., a royalty-holding company for GlaxoSmithKline respiratory drugs, has weekly stock performance that reflects sales of these drugs. Sales data and news about competition in asthma and COPD treatments drive short-term fluctuations, revealing a passive yet sensitive business model.
Weekly dynamics of market capitalization of the market segment - Investors holding
Innoviva, as a royalty holder, is part of the pharmaceutical sector. The chart compares its performance with the industry to see how much of its weekly fluctuations are driven by general pharma news and how much by specific sales data for the drugs on which it receives royalties.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Innoviva is a holding company that receives royalties from GSK's respiratory drugs. Its business model ensures stable cash flow. The chart will show whether INVA shares act as a defensive, dividend-paying asset, less volatile than the market and even the pharmaceutical sector.
Market capitalization of the company, segment and market as a whole
INVA - Market capitalization of the company Innoviva Inc.
The Innoviva chart represents a financial portfolio of respiratory drug royalties. Its market capitalization reflects the stable cash flow from GlaxoSmithKline's asthma and COPD medications. Its dynamics demonstrate how investors assess the longevity of these royalties and the company's strategy for reinvesting capital into new assets.
INVA - Share of the company's market capitalization Innoviva Inc. within the market segment - Investors holding
Innoviva is a company with a unique business model, earning royalties from respiratory drugs developed jointly with GlaxoSmithKline. Its market capitalization reflects the value of these stable cash flows. The chart below shows how the market values this royalty portfolio and the company's reinvestment strategy.
Market capitalization of the market segment - Investors holding
Innoviva is a company that receives royalties from sales of GSK respiratory drugs. The chart below shows the overall market capitalization of the entire pharmaceutical industry. Its dynamics provide a backdrop against which Innoviva's unique business model, based on passive income, becomes particularly compelling.
Market capitalization of all companies included in a broad market index - GURU.Markets
Innoviva is a company that receives royalties from sales of respiratory drugs developed by GSK. Its market capitalization chart is a unique story of intellectual property monetization. It demonstrates how passive income from successful drugs can create stable and predictable value.
Book value capitalization of the company, segment and market as a whole
INVA - Book value capitalization of the company Innoviva Inc.
Innoviva is a company that receives royalties from GSK's respiratory drugs. Its book value is its accumulated capital. The chart below shows the financial results of its unique business model, not its production assets. Growth in this chart represents the successful collection and reinvestment of royalties.
INVA - Share of the company's book capitalization Innoviva Inc. within the market segment - Investors holding
Innoviva is a company that owns royalties on GSK's respiratory drugs. Its business model is to generate passive income from its intellectual property. The tangible assets percentage chart will be negligible, showing how the company generates profits without owning any factories or laboratories.
Market segment balance sheet capitalization - Investors holding
Innoviva manages a portfolio of royalties from respiratory drugs developed by GSK. Its business is focused on generating passive income, not R&D or manufacturing. The book value chart reveals a unique "lightweight" model, where the core assets are rights to future cash flows, not tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
Innoviva's assets are a portfolio of royalties from leading respiratory drugs. The company's book value reflects not the manufacturing plants, but rather the rights to receive a portion of the revenue from sales of drugs developed by GlaxoSmithKline. The chart shows the value of these long-term rights, which generate a stable cash flow for the company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Innoviva Inc.
Innoviva holds royalties from respiratory drugs developed by GlaxoSmithKline. It has virtually no operating business or tangible assets. Its entire market capitalization is the current estimate of future cash flows from these royalties. The chart shows how investors discount these future revenues.
Market to book capitalization ratio in a market segment - Investors holding
Innoviva, Inc. owns a portfolio of royalties from respiratory drugs developed by GSK. Its primary asset is the right to receive future cash flows. The chart shows how the market values these flows, taking into account the patent lifespan, comparing the market capitalization with the book value of these rights.
Market to book capitalization ratio for the market as a whole
Innoviva is a company that receives royalties from respiratory medications sold by GlaxoSmithKline. Its main asset is not its manufacturing facilities, but rather the right to receive cash flows from its intellectual property. The chart shows how the market values the stability and longevity of these royalties, which represents a unique business model with almost no tangible assets.
Debts of the company, segment and market as a whole
INVA - Company debts Innoviva Inc.
Innoviva, a company that earns royalties from respiratory drugs, uses its unique business model to manage debt. This chart may reflect raising funds secured by future cash flows to invest in other biotech companies. Debt here is a way to monetize existing assets to create new ones.
Market segment debts - Investors holding
Innoviva is a holding company that owns royalties from respiratory drugs developed by GSK. The royalty-based business model generates stable cash flow. Debt in this structure can be used to acquire new assets or return capital to shareholders. The chart shows how the company manages its capital.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Innoviva Inc.
Innoviva owns a portfolio of royalties from respiratory drugs developed by GSK, providing it with stable cash flow. This chart shows how the company utilizes its capital. The presence of debt may indicate a strategy of diversification and investment in new assets, which carries both growth potential and new risks for investors.
Market segment debt to market segment book capitalization - Investors holding
Innoviva is a company that receives royalties from respiratory drugs developed by GSK. It also invests in emerging biotech and medical device companies. This hybrid model is unique. The chart shows the overall debt load in the sector, providing context for assessing how Innoviva uses its stable royalties for risky venture investments.
Debt to book value of all companies in the market
Innoviva, which receives royalties and invests in biotech, has a unique model. This chart shows the overall market leverage, reflecting risk appetite. It helps assess how the value of its venture investments fluctuates depending on overall market sentiment, and how stable its royalty income is under these conditions.
P/E of the company, segment and market as a whole
P/E - Innoviva Inc.
Innoviva is a company that receives royalties from respiratory drugs developed by GlaxoSmithKline. This chart shows investors' assessment of the stability and longevity of these cash flows. The dynamics of this indicator depend on the sales volumes of the underlying drugs and the validity of the patents, which provide the company with predictable income.
P/E of the market segment - Investors holding
Innoviva represents a unique sector of royalty-paying companies in the pharmaceutical industry. This chart shows the average P/E for this niche. Comparing the company's P/E to this metric helps understand whether the market considers its respiratory drug royalty portfolio more durable and reliable than other companies generating passive income from intellectual property.
P/E of the market as a whole
Innoviva is a company that receives royalties from respiratory drugs sold by GlaxoSmithKline. Its business model generates a stable cash flow, which it reinvests. This chart shows overall market sentiment. It helps understand whether Innoviva is valued as a stable dividend-paying company based on royalties, or whether its investments in new projects add an element of risk and growth.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Innoviva Inc.
Innoviva holds a portfolio of royalties from respiratory drugs developed by GSK. This chart reflects market expectations regarding the stability of these cash flows and the company's success in diversifying its investments. Future profits depend on drug sales volumes and the success of the company's new investments.
%20P%2FE%20Innoviva%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Innoviva-Inc.&v=1772647694191 "Chart of the company's future (projected) P/E Innoviva Inc.")
Future (projected) P/E of the market segment - Investors holding
Innoviva is a company that receives royalties from respiratory drugs developed by GlaxoSmithKline. This chart shows how the market values the company's future cash flows. It reflects investor expectations regarding the patent lifespan and Innoviva's ability to reinvest its profits into new, promising healthcare assets.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Investors%20holding&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Investors-holding&v=1772647694208 "Future (projected) P/E graph of the market segment - Investors holding")
Future (projected) P/E of the market as a whole
Innoviva is a company that receives royalties from respiratory drugs developed by GSK. Its business model provides stable cash flow, but the company also invests in new projects. The overall market environment, visible in this chart, influences the valuation of these investments and the cost of capital that Innoviva can raise to diversify its portfolio.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772647694221 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Innoviva Inc.
Innoviva is a company that receives royalties from sales of leading respiratory drugs developed by GSK. Its business model ensures a stable cash flow with high profitability. This chart clearly demonstrates how sales volumes from partner drugs directly translate into near-net income for the company, driving its financial results.
Profit of companies in the market segment - Investors holding
Innoviva manages a portfolio of royalties from leading respiratory drugs developed by GSK. This chart, which shows overall profits in the pharmaceutical sector, demonstrates the value of intellectual property. Innoviva's stable cash flows from blockbuster sales demonstrate how successful drugs can generate long-term profits for the entire ecosystem.
Overall market profit
Innoviva manages a portfolio of royalties from respiratory drugs developed by GSK. This provides the company with a stable and predictable cash flow. Innoviva's business model, based on passive income from already successful products, makes it less dependent on economic cycles and the risks of new drug development, distinguishing it from other pharmaceutical companies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Innoviva Inc.
Innoviva is a company that receives royalties from respiratory medications sold by GlaxoSmithKline. The future profit projections reflected here depend on sales volumes of these medications. Analysts assess the dynamics of the asthma and COPD drug market, as well as the company's strategy for reinvesting royalties into new assets.
%20profit%20of%20the%20company%20Innoviva%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Innoviva-Inc.&v=1772647694335 "Graph of future (projected) profit of the company Innoviva Inc.")
Future (predicted) profit of companies in the market segment - Investors holding
Innoviva manages a portfolio of royalties from respiratory drugs developed by GSK. The company also invests in promising new assets in the healthcare sector. This chart shows profit forecasts for the holding company-investor sector. It helps understand how the company's strategy, combining stable cash flow and venture capital investments, compares to overall market expectations.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Investors%20holding&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Investors-holding&v=1772647694370 "Graph of future (predicted) profits of companies in a market segment - Investors holding")
Future (predicted) profit of the market as a whole
Innoviva is a holding company that receives royalties from respiratory medications sold by GlaxoSmithKline. Its revenues are stable and based on patent protection. This graph is less influenced by the overall economic situation. However, the company also invests in new assets, and market conditions play a role in the valuation and availability of deals.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772647694378 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Innoviva Inc.
Innoviva is a company that owns a portfolio of royalties from respiratory drugs developed by GSK. This chart, which compares market capitalization with royalty flow, demonstrates the valuation of its unique business model. It shows how stable and valuable investors consider this source of passive income and whether they believe in its ability to reinvest these funds.
P/S market segment - Investors holding
Innoviva has a unique business model, receiving royalties from respiratory medications sold by GlaxoSmithKline. This provides a stable cash flow, which the company reinvests. This chart shows how the market values royalty-based revenue, providing insight into how investors view the long-term sustainability of these revenue streams and Innoviva's capital allocation strategy.
P/S of the market as a whole
Innoviva, Inc. receives royalties from GSK for respiratory drugs developed in partnership with Theravance Biopharma. The company's business model is based on passive income from intellectual property. This chart helps investors understand how the market values this unique royalty model compared to traditional operating companies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Innoviva Inc.
Innoviva, Inc. receives royalties from respiratory medications sold by GlaxoSmithKline. This chart shows how investors value the company based on its future royalty streams. It reflects expectations for sales volumes of these medications, patent expirations, and the success of the company's investments in new pharmaceutical assets.
%20P%2FS%20Innoviva%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Innoviva-Inc.&v=1772647694630 "The graph of the company's future (projected) P/S Innoviva Inc.")
Future (projected) P/S of the market segment - Investors holding
Innoviva is a company that holds a portfolio of royalties from respiratory drugs developed by GSK. This figure shows how the market values the company's future earnings. This estimate reflects investors' opinions on the stability and longevity of these royalties, as well as the success of the company's strategy to reinvest cash flows into new healthcare assets.
%20P%2FS%20market%20segment%20graph%20-%20Investors%20holding&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Investors-holding&v=1772647694654 "Future (projected) P/S market segment graph - Investors holding")
Future (projected) P/S of the market as a whole
Innoviva is a company that receives royalties from sales of respiratory drugs developed by GSK. Its business model ensures stable cash flow with minimal operating costs. This graph of general investor expectations reflects their view of the pharmaceutical market and the attractiveness of business models based on intellectual property.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772647694665 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Innoviva Inc.
Innoviva's revenue is unique in that it consists almost entirely of royalties. The company generates passive income from sales of successful respiratory drugs developed by its partner GlaxoSmithKline. This income growth is directly dependent on the success of these drugs in the global market, without incurring any marketing expenses of its own.
Sales of companies in the market segment - Investors holding
Innoviva is a company that owns a portfolio of royalties on respiratory drugs developed in partnership with GlaxoSmithKline. The company's business model is to generate passive income from drug sales. This chart shows its total pharmaceutical sales revenue, a portion of which Innoviva receives in the form of royalties.
Overall market sales
Innoviva, Inc. receives royalties from respiratory medications sold by GlaxoSmithKline. Its revenue is stable and based on patent agreements. Although the company is not directly affected by economic cycles, the overall situation shown in this chart influences the stock market and asset valuations, which is important for its strategy of reinvesting revenues into new assets.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Innoviva Inc.
Innoviva is a company that owns a portfolio of royalties from respiratory drugs developed by GSK. Its revenues come from passive payments from sales of these drugs. This chart reflects analysts' forecasts for future sales of these drugs and the company's strategy for diversifying its assets.
%20sales%20of%20the%20company%20Innoviva%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Innoviva-Inc.&v=1772647694711 "Schedule of future (projected) sales of the company Innoviva Inc.")
Future (projected) sales of companies in the market segment - Investors holding
Innoviva is a company that receives royalties from respiratory drugs developed by GlaxoSmithKline. This chart details projected royalty revenues for specific drugs, such as Relvar/Breo Ellipta. This gives investors a clear understanding of analysts' estimates of these drugs' future sales volumes and the company's cash flow stability.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Investors%20holding&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Investors-holding&v=1772647694731 "Schedule of future (projected) sales of companies in the market segment - Investors holding")
Future (projected) sales of the market as a whole
This chart illustrates the investment climate affecting Innoviva. The holding company owns royalties from respiratory drugs. The stability of these cash flows allows it to invest in other healthcare assets, while opportunities for new deals depend on the overall valuation and activity in the biotech market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772647694763 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Innoviva Inc.
Innoviva has a unique business model: it owns the royalty rights to the leading respiratory drugs sold by GSK. This chart demonstrates the high profitability of this approach. The company generates a stable revenue stream with minimal operating costs, converting the majority of revenue directly into profit.
Market segment marginality - Investors holding
Innoviva is a company that owns royalties from respiratory medications sold by GlaxoSmithKline. Its low-operating-cost business model ensures high profitability. This chart shows profitability in related sectors. It helps assess the stability and profitability of the royalty stream, which is the foundation of Innoviva's business.
Market marginality as a whole
Innoviva is a holding company that owns royalties from respiratory medications sold by GlaxoSmithKline. Its revenue is entirely dependent on sales volumes of these drugs. Although demand for them is relatively stable, the overall economic situation, reflected in this chart, can impact healthcare systems and drug pricing in the long term.
Employees in the company, segment and market as a whole
Number of employees in the company Innoviva Inc.
Innoviva, Inc. receives royalties from respiratory medications sold by GlaxoSmithKline. This chart reflects the very compact team managing these financial streams. A small and stable staff is characteristic of a business model based on generating passive income from intellectual property rather than on operational or R&D activities.
Share of the company's employees Innoviva Inc. within the market segment - Investors holding
Innoviva is a company that receives royalties from respiratory drugs developed by GSK. Its model doesn't require a large staff, but key employees manage enormous cash flows. This chart likely shows a small percentage, highlighting the uniqueness of its business model, which is based on intellectual property rather than operations.
Number of employees in the market segment - Investors holding
Innoviva, Inc. manages a royalty portfolio, generating revenue from leading respiratory drugs developed in partnership with GSK. This chart shows employment in the investment holdings sector. Although the company does not conduct R&D itself, employment dynamics in the pharmaceutical industry generally reflect the state of the industry, which determines the long-term value of its assets and future opportunities.
Number of employees in the market as a whole
Innoviva is a holding company for GSK's portfolio of respiratory royalties. Their revenues are stable and based on drug sales. This general employment schedule does not affect their core business. The company's future growth and personnel decisions will depend on the success of new investments, not the labor market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Innoviva Inc. (INVA)
Innoviva is a company that owns royalties from respiratory drugs sold by GSK. It has very few employees, and its value is based on the royalty flow. This chart shows an extremely high cost per employee, as the revenue is generated by intellectual property, and only a small team is required to manage it.
%20of%20the%20company%20Innoviva%20Inc.%20(INVA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Innoviva-Inc.-INVA&v=1772647694875 "Chart of market capitalization per employee (in thousands of dollars) of the company Innoviva Inc. (INVA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Investors holding
Innoviva (INVA) is a company that receives royalties from GSK for leading respiratory drugs (e.g., Relvar/Breo). They have virtually no operational activities; their business is primarily collecting royalties. This figure would be very high, as their enormous market value is supported by a minimal staff.
%20by%20market%20segment%20-%20Investors%20holding&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Investors-holding&v=1772647694883 "Market capitalization per employee (in thousands of dollars) by market segment - Investors holding")
Market capitalization per employee (in thousands of dollars) for the overall market
Innoviva is a company that owns a portfolio of royalties from respiratory drugs developed by GSK. Its business model is based on generating passive income. This income will be very high, as the company has a minimal staff, and its capitalization is based on the value of future cash flows from successful drugs developed by another company.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772647694893 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Innoviva Inc. (INVA)
Innoviva isn't a traditional pharma company. Their business is holding royalties on key respiratory drugs (for example, from GSK). They have almost no operational activities and very few employees. This chart demonstrates extreme financial leverage: a huge stream of passive income (royalties) is divided among a tiny staff, resulting in a gigantic profit per employee.
%20Chart%20Innoviva%20Inc.%20(INVA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Innoviva-Inc.-INVA&v=1772647694910 "Company Profit Per Employee (in thousands of dollars) Chart Innoviva Inc. (INVA)")
Profit per employee (in thousands of dollars) in the market segment - Investors holding
Innoviva is a royalty-based company. They earn passive income (royalties) from GSK's (GlaxoSmithKline) respiratory drugs. This chart shows the benchmark for investment holdings (royalties). In this asset-light sector, the benchmark is prohibitively high. Profit per employee (their "units") is generated by patents, not labor.
%20in%20the%20market%20segment%20-%20Investors%20holding&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Investors-holding&v=1772647694915 "Chart of profit per employee (in thousands of dollars) in the market segment - Investors holding")
Profit per employee (in thousands of dollars) for the market as a whole
Innoviva is an atypical company. They don't do R&D, but rather hold royalties from respiratory drugs developed by GlaxoSmithKline. They simply collect checks. It's a "mailbox" business model. This chart clearly demonstrates how much the royalty-collecting business, which requires virtually no staff, differs in profitability per employee from the rest of the economy.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772647694917 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Innoviva Inc. (INVA)
Innoviva is a company that receives royalties from respiratory drugs developed by GSK. Its revenue per employee is extremely high because it owns the patents rather than sells them. The graph shows a steady royalty stream generated by a very small management team, which is the essence of its business model.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Innoviva-Inc.-INVA&v=1772647694934 "Sales chart per company employee Innoviva Inc. (INVA)")
Sales per employee in the market segment - Investors holding
Innoviva (INVA) is an atypical "pharma." They don't conduct their own R&D, but rather own the rights (royalties) to respiratory drugs sold by GSK (for example, Relvar/Breo). They have a very small staff. This chart shows how effective their model is. Their tiny team generates huge revenues simply by collecting royalty checks.
Sales per employee for the market as a whole
Innoviva (INVA) is an atypical company. It owns the royalty rights from leading respiratory drugs (for COPD/asthma) sold by GSK. Their business is collecting royalties. This chart demonstrates their maximum operating leverage. Innoviva has a very small staff, which simply manages these financial assets (royalties). Hundreds of millions in revenue accrue automatically, resulting in one of the highest revenue ratios.
Short shares by company, segment and market as a whole
Shares shorted by company Innoviva Inc. (INVA)
Innoviva (INVA) is an atypical company. Its core business is receiving royalties from GSK for its leading respiratory drugs (for asthma and COPD). This chart shows the number of bearish bets. Bears may fear patent expiration on these blockbusters, leading to the emergence of generic versions and a sharp decline in royalty revenue—the company's primary source of income.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Innoviva-Inc.-INVA&v=1772647694984 "Short Shares Chart for the Company Innoviva Inc. (INVA)")
Shares shorted by market segment - Investors holding
Innoviva (INVA) owns a portfolio of royalties from respiratory drugs developed by GSK (e.g., Relvar/Breo). They receive passive income from these sales. This chart shows bets against the holding investor sector. Shorts here can be specific: investors fear patent expirations on key drugs or increased generic competition, which would depress royalty flows.
Shares shorted by the overall market
Innoviva (INVA) is a holding company that owns royalties on GSK drugs. This indicator (`Short_All`) is a proxy for market fear. When it rises, investors panic and shed risk. This pessimism weighs on INVA, as investors fear patent expirations in uncertain times.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Innoviva Inc. (INVA)
Innoviva owns royalties on GSK's respiratory drugs. Its business model is relatively stable but depends on sales of these drugs. A chart above 70 may reflect strong drug sales or new deals. A level below 30 is often associated with concerns about generic competition or slowing sales.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Innoviva-Inc.-INVA&v=1772647695040 "RSI 14 indicator chart for the company's stock Innoviva Inc. (INVA)")
RSI 14 Market Segment - Investors holding
Innoviva (INVA) is a company that doesn't develop drugs itself, but rather holds royalties from respiratory drugs sold by GSK (such as Relvar/Breo). It uses this cash flow to invest in other assets. This chart shows the general sentiment in the pharmaceutical royalty and holdings sector. It helps assess how investors view this unique business model, separating it from R&D risks.
RSI 14 for the overall market
Innoviva (INVA) owns royalties from respiratory drugs. This chart shows that its business is "defensive." Demand for asthma drugs isn't affected by euphoria or panic. During times of market panic, investors seek safe havens in companies with stable, predictable cash flow, like INVA.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast INVA (Innoviva Inc.)
Innoviva (INVA) is a holding company whose business model is based on royalties from respiratory drugs sold by GlaxoSmithKline (e.g., Relvar/Breo). The chart shows the average target price from analysts, reflecting their assessment of the stability of this cash flow and the potential for Innoviva's new biotech investments.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-INVA-Innoviva-Inc.&v=1772647695079 "A chart showing analyst consensus forecasts for the expected stock price. INVA (Innoviva Inc.)")
The difference between the consensus estimate and the actual stock price INVA (Innoviva Inc.)
Innoviva is a holding company whose core business is collecting royalties from GSK for blockbuster treatments for respiratory diseases (asthma, COPD). This chart shows the difference between the consensus estimate and the price. It reflects whether analysts believe in the longevity of these cash flows and whether they see potential.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-INVA-Innoviva-Inc.&v=1772647695106 "A chart showing the difference between the consensus forecast and the actual stock price. INVA (Innoviva Inc.)")
Analyst consensus forecast for stock prices by market segment - Investors holding
Innoviva (INVA) is a holding company whose primary asset is royalties from GSK's respiratory drugs (Breo, Anoro). It uses this cash flow to invest in other healthcare assets. This chart shows analysts' overall expectations for the investment holdings sector, reflecting whether experts believe in the reinvestment strategy.
Analysts' consensus forecast for the overall market share price
Innoviva is a unique company that relies on royalties (from GSK) on drugs for respiratory diseases. Demand for these drugs is non-cyclical. This chart, which shows overall market sentiment, is important in reverse. During a recession (pessimism), investors value the security and predictability of Innoviva's cash flow.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Innoviva Inc.
Innoviva is an atypical pharma company. They don't develop drugs, but rather hold royalties (rights to a percentage of sales) on leading respiratory medications sold by GlaxoSmithKline. This chart is essentially a comprehensive assessment of their cash flow. It reflects market expectations for sales of these blockbusters and the durability of their patent protection.
AKIMA Market Segment Index - Investors holding
Innoviva is a pharma fintech (like Royalty Pharma). The company doesn't invent drugs, but rather holds a portfolio of royalties (payments) on GlaxoSmithKline blockbusters (primarily for asthma treatments). This comprehensive index evaluates R&D models. The chart shows the average value for the segment. This benchmark: how does this asset-light royalty model (INVA) differentiate it from the average, traditional pharma company?
The AKIM Index for the overall market
Innoviva is a royalty management company that generates revenue from a portfolio of respiratory drugs (in partnership with GSK). This is a financial model in the pharmaceutical industry. This chart, reflecting the market average, is the backdrop. It helps assess how this cash flow, which depends on drug sales rather than the economy, compares to general macroeconomic fluctuations.
